downloadDownload

Phase II/III randomised multicentre trial using a factorial design evaluating the advantage (i) of a strategy of primary surgery vs primary chemotherapy and (ii) chemotherapy with XELOX vs ECF in resectable gastric signet ring cell adenocarcinomas.

assignment_turned_inproject

Funder: Institut National du CancerProject code: INCa-DGOS-3768 Call for proposal: PHRC11

Funded under: PHRC

Phase II/III randomised multicentre trial using a factorial design evaluating the advantage (i) of a strategy of primary surgery vs primary chemotherapy and (ii) chemotherapy with XELOX vs ECF in resectable gastric signet ring cell adenocarcinomas.

- Summary
- DMPs

Data Management Plans

Start a new DMP in Argos

Select content type to embed

All Research products

arrow_drop_down

<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=inca________::971edca5469b2c2b866ba39706372a24&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

Phase II/III randomised multicentre trial using a factorial design evaluating the advantage (i) of a strategy of primary surgery vs primary chemotherapy and (ii) chemotherapy with XELOX vs ECF in resectable gastric signet ring cell adenocarcinomas.

Phase II/III randomised multicentre trial using a factorial design evaluating the advantage (i) of a strategy of primary surgery vs primary chemotherapy and (ii) chemotherapy with XELOX vs ECF in resectable gastric signet ring cell adenocarcinomas.

Loading